Menu Search
Equities

Zevra Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1GDA:MUN

Zevra Therapeutics Inc

Actions
  • Price (EUR)7.20
  • Today's Change-0.55 / -7.10%
  • Shares traded250.00
  • 1 Year change-7.69%
  • Beta0.9322
Data delayed at least 15 minutes, as of Feb 06 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

  • Revenue in USD (TTM)84.39m
  • Net income in USD35.33m
  • Incorporated2014
  • Employees59.00
  • Location
    Zevra Therapeutics Inc1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION 34747United StatesUSA
  • Phone+1 (321) 939-3416
  • Fax+1 (302) 636-5454
  • Websitehttps://zevra.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.